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Abstract
Background: Small studies suggest differences in efficacy and safety exist between olive oil-based (OLIVE) and soybean
oil-based (SOYBEAN) parenteral nutrition regimens in hospitalized adult patients. This large, prospective, randomized (1:1),
open-label, multi-center, noninferiority study compared the delivery, efficacy, and safety of OLIVE (N = 226) with SOYBEAN
(N = 232) in Chinese adults (≥18 years) admitted to a surgical service for whom parenteral nutrition was required.
Methods: Treatments were administered for a minimum of 5 days up to 14 days (to achieve approximately 25 kcal/kg/
day, 0.9 g/kg/day amino acids, 0.8 g/kg/day lipid). Impact of treatment on anabolic/catabolic and serum inflammatory,
chemistry, and hematological markers, safety, and ease of use were assessed. The primary efficacy variable was serum
prealbumin level at Day 5.
Results: OLIVE (n = 219) was not inferior to SOYBEAN (n = 224) based on the prealbumin least square geometric mean
[LSGM] ratio [95 % CI] 1.12 [1.06, 1.19]; P = 0.002), improved the anabolic/catabolic status of patients enrolled in the study,
and was well tolerated compared with SOYBEAN. Improved anabolic status was supported by significantly higher levels
of prealbumin at Day 5, albumin at Day 5 and IGF-1 at Day 14 in the OLIVE group, while catabolism was similar between
groups. C-reactive protein, intercellular adhesion molecule-1, procalcitonin, and oxidation were similar in each group, but
infections were significantly lower with OLIVE (3.6 % versus 10.4 %; P < 0.01).
Conclusions: OLIVE provided effective nutrition, was well tolerated, was associated with fewer infections, and conferred
greater ease-of-use than SOYBEAN.
Trial registration: NTC 01579097.
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Background
The beneficial effects of parenteral nutrition (PN) in ill
patients unable to tolerate adequate enteral feeding are
well established [1–3]. PN not only improves nutritional
status in malnourished patients, it also reduces compli-
cations [4, 5] such as infections, need for mechanical
ventilation, and muscle weakness. As a result, PN is an
important therapeutic modality for treating patients with
compromised intestinal function.
Animal and human studies suggest that the lipid
source in PN, and more specifically the fatty-acid com-
position of the lipid source, may contribute to the risk of
complications [6–9]. Such complications include inflam-
mation, oxidation, immune compromise, infections,
hyperglycemia, and liver dysfunction/failure. Soybean
oil-based lipid emulsions are composed of long-chain
triglycerides, primarily linoleic acid (ω-6 polyunsaturated
fatty acids [PUFAs]). In contrast, olive oil-based lipid
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emulsions are composed of long-chain triglycerides, pri-
marily oleic acid (ω-9 monounsaturated fatty-acids
[MUFAs]) [10]. According to the 2012 American Society
for Parenteral and Enteral Nutrition (ASPEN) Novel Nu-
trient Task Force, lipid sources such as safflower oil and
soybean oil are considered pro-inflammatory, while olive
oil is considered immune neutral [10]. Experimental re-
ports suggest that ω-6 PUFA-rich lipid emulsions that
are derived from soybean oil may exaggerate the inflam-
matory response associated with stress and trauma via
activation of the arachidonic acid eicosanoid pathway
and have direct effects on lymphocyte, macrophage, and
neutrophil functions [11–14]. These ω-6 PUFA effects
upon inflammation and immune cell functions may in-
crease the rate of infections. As a result, lipid emulsions
with lower linoleic acid levels (ie, olive oil predominant
emulsions) have been developed. However, there are lim-
ited data to suggest that the replacement of soybean oil-
based ω-6 PUFAs with olive oil-based ω-9 MUFAs
improves the safety of PN [15, 16]. Therefore, one of the
objectives of this study was to evaluate the incidence of
infections using two different lipid emulsions that varied
in the content of linoleic acid.
In this study, we utilized two different PN regimens
differing in lipid emulsion type (olive oil based versus
soybean oil based) and delivery system (compounded
versus a ready-to-use, three-chamber bag). The primary
endpoint chosen was prealbumin level (an index of ana-
bolic and inflammatory status). Due to the lower ω-6
PUFA content (a pro-inflammatory fatty acid) and
higher oleic acid content (MUFA with lower oxidation
risk) of the olive-oil based lipid emulsion, we hypothe-
sized that this emulsion would be associated with im-
proved anabolic/catabolic status. Anabolism was
assessed using prealbumin, albumin, and insulin growth
factor-1 (IGF-1) levels. Catabolism was assessed using
the protein breakdown end-products of urea and 3-
methylhistidine. We also assessed inflammation (inter-
leukin-6 [IL-6], C-reactive protein [CRP], intercellular
adhesion molecule-1 [ICAM-1]) and oxidation (malonyl-
dialdehyde, F2-isoprostanes) biomarkers. By measuring
anabolic, catabolic, and inflammatory parameters, we
were able to compare changes in anabolic parameters in
patients with similar inflammatory and catabolic status.
In addition to these nutritional parameters, we assessed
clinical outcomes using infections (a marker of immune
status), hospital length of stay, mortality, and adverse
events. Safety was assessed by measuring biomarkers of
organ functions (liver, renal, hematologic, and endo-
crine). Because a ready-to-use formulation is immedi-
ately available to clinicians (no need to compound), we
also assessed preparation time.
Although several small studies have investigated the
differences between soybean oil-based and olive oil-
based lipid emulsions, it remains unclear whether the re-
placement of ω-6 PUFAs with ω-9 MUFAs results in im-
proved efficacy and safety. To address this shortcoming,
the objectives of this study were to assess the delivery,
efficacy, and safety of an olive oil-based lipid PN regi-
men compared with a compounded soybean oil-based
lipid PN regimen in Chinese adults for whom oral or en-




The study was an open-label, prospective, randomized
(1:1), comparative, multi-center, active-controlled,
parallel-group investigational trial (NTC 01579097)
conducted in 18 centers across China. Ethics approval
was obtained from the Institutional Ethics Commit-
tees and written informed consent was obtained be-
fore enrolment of any patients into the clinical trial.
The study was conducted between December 29, 2011
and November 21, 2012 and was centrally administrated
by Global Clinical Development & Operations (CD&O)
based in Baxter Alliance Park, Belgium.
Study population
Patients admitted to a surgical service were eligible for
enrolment into the trial if all of the following criteria
(and none of the exclusion criteria) were met: aged ≥18
to ≤80 years old; an inpatient that was hospitalized ≤14 days
before enrolment; required PN because oral or enteral
nutrition was not possible, insufficient, or contraindicated;
had the capability to complete at least five days of study
treatment (ie, PN); had a useable peripheral vein for intra-
venous (IV) delivery of PN; and was able to complete writ-
ten informed consent per national regulations. Exclusion
criteria were: a life expectancy of <6 days from initiation of
study treatment; a known hypersensitivity to the compo-
nents of the study treatments; use of prohibited medica-
tions within 30 days before enrolment; a known serious
clinically significant condition such as congestive heart fail-
ure or severe renal insufficiency (renal failure that was not
compensated for by hemofiltration or dialysis; patients un-
able to tolerate fluid load from PN); impaired hepatic func-
tion (total bilirubin >2 times the upper limit of normal; or
alanine transaminase >4 times the upper limit of normal;
or aspartate transaminase >4 times the upper limit of
normal); a known history of human immunodeficiency
virus infection; known congenital abnormalities of amino
acid metabolism; known severe dyslipidemia (triglyceride
level >2 times the upper limit of normal or >400 mg/dL or
>4.52 mmol/L) or hyperglycemia (blood glucose >360 mg/
dL); clinically significant abnormalities of plasma electro-
lytes; currently pregnant or lactating; prior enrolment in
this clinical trial; participation in a clinical trial of any
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investigational drug or device concomitantly or within
30 days before enrolment in this clinical trial; or was con-
sidered unsuitable in the opinion of the Investigator. Due
to clinical and resource constraints, consecutive patients
were not enrolled at each center.
Treatment protocol
Patients were randomized to either an olive oil-based
lipid PN regimen using OliClinomel N4 (OLIVE; Baxter
Healthcare, Deerfield, IL, USA) or a compounded soy-
bean oil-based lipid PN regimen using Intralipid (SOY-
BEAN; Sino-Swed Pharmaceutical Corporation, Ltd.,
Wuxi City, China).
OLIVE was supplied as a ready-to-use PN product
presented as a three-chamber bag (1.5 l) comprising a
larger outer chamber that contains a dextrose (D-glu-
cose) solution (final mixed concentration 80 g/l) with
calcium (final mixed concentration 2 mmol/l); a middle
chamber that contains a solution of 15 amino acids (final
mixed concentration 22 g/L), with electrolytes including
sodium (final mixed concentration 21 mmol/L),
potassium (final mixed concentration 16 mmol/L), mag-
nesium (final mixed concentration 2.2 mmol/L), and
phosphate (final mixed concentration 8.5 mmol/L); and
a smaller outer chamber that contains a lipid emulsion
comprising 80 % olive oil and 20 % soybean oil (final
mixed concentration 20 g/L).
SOYBEAN was prepared as a compounded admixture
by the institutional pharmacy (1.5 l), specifically the Phar-
macy Intravenous Admixture Services if available, per the
investigators’ prescription. Components were manufac-
tured by: dextrose – 20 % Glucose 500 mL (Baxter (China)
Investment Co., Ltd., Shanghai, China); amino acids –
amino acid 15-AA 250 mL:20 g (8 %; Hunan Kelun
Pharma Co., Ltd, Yueyang City, China); and lipid –
Intralipid® 10 g/dL (Sino-Swed Pharmaceutical Corpor-
ation, Ltd., Wuxi City, China). The final concentrations of
dextrose, protein, and lipid were the same as for OLIVE.
Electrolytes, vitamins, and trace elements could be
added to the study treatment or compounded PN based
upon patient requirements. The study treatment was in-
fused through a peripheral IV catheter via a control
pump. If continued infusion via a peripheral IV was not
possible, the study treatment could be infused via a
peripherally-inserted central catheter or central IV line.
Study treatment was administered for a minimum of five
days and up to a maximum of 14 days (either 14 days after
surgery or 14 days total for patients who did not undergo
surgery). Study treatment could be initiated up to three
days before surgery and was administered after surgery on
Day 1 at Hour 0. Preoperative PN was not mandatory and
if a patient did not receive study treatment before surgery,
or if the patient was not scheduled for surgery, study treat-
ment was initiated on Day 1 at Hour 0.
From Day 0 to Day 5, patients were not to receive any
food or liquid oral or enteral nutrition. The goal of treat-
ment was to deliver 25 kcal/kg/day, 0.9 g/kg/day amino
acids, and 0.8 g/kg/day lipid. The patients were allowed
water and ice chips based on the clinical judgment of
the Investigator.
From Day 6 through the remainder of the study treat-
ment period, liquid oral or enteral nutrition could be
added to the study treatment. The intent was to supply
the total calculated daily nutritional requirement with
study treatment (intravenous nutrition) plus liquid oral
or enteral nutrition. Liquid oral or enteral nutrition was
increased daily, as tolerated by the patient, with a con-
current reduction in study treatment, while still supply-
ing the calculated daily nutritional requirement.
Study treatment was ceased once the patient was able
to achieve ≥80 % of the calculated daily nutritional re-
quirements by administered liquid oral or enteral nutri-
tion, or the completion of Day 14 study treatment,
whichever occurred earlier.
Randomization
Assignment of study treatment was delegated by Baxter
Healthcare Corporation to the study site pharmacist. Pa-
tient numbers were allocated using an Interactive Voice
Recognition System/Interactive Web-based Recognition
System according to the randomization code contained
within the randomization list.
This was an open-label study. Treatment assignment
was not known (ie, blinded) by the data management,
biostatistical, and personnel at the central laboratory. In
order to prepare the study treatment, the designated
pharmacist was aware of the study treatment (un-
blinded). The study treatment was unblinded to the In-
vestigator as it was standard practice that the physician
and/or nurse carefully inspect the PN admixture to en-
sure that the integrity of the admixture was maintained
throughout the length of the infusion.
Outcome measures
The primary efficacy variable was the serum prealbumin
level at Day 5. Secondary efficacy outcome(s) included
preparation time of study treatment, time to achieve
tolerability of oral nutrition, length of hospitalization,
lipids and lipid upper derivatives (arachidonic acid, ei-
cosapentaenoic acid [EPA], linoleic acid, oleic acid),
markers of infection and inflammation (cortisol, CRP,
procalcitonin, serum ICAM-1, IL-6), markers of oxida-
tive stress (malondialdehyde, F2-isoprostane), surrogate
markers of nutrition (albumin, IGF-1), urine markers of
metabolism (6-h urinary urea, 3-methylhistidine), and
injection site rating by the Investigator. Safety outcomes
included total adverse events (AEs), liver function, and
infections. Infections were based upon the clinical
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judgment of the investigators and utilized cultures when
possible. Antibiotics were administered for all infections.
Lung infections were defined as: the new onset of fever
and/or leukocytosis with or without alterations in men-
tation, purulent sputum or organisms on smear or cul-
ture, and a new progressive or persistent infiltrate on
chest X-ray consistent with pneumonia (with no other
obvious cause). Scrotal infection was diagnosed by the
presence of fever and/or leukocytosis, new evidence of
infection in the scrotum (pain, tenderness, swelling,
heat, redness), and no other recognized cause for the
abnormality. Non-specific infection was diagnosed in a
patient with new fever, leukocytosis, tachycardia, tachyp-
nea and no other obvious cause for the abnormalities,
and a response to antibiotic treatment. These outcomes
were approved by the China State Food and Drug
Administration as being sufficient to register the OLIVE
product in China.
Statistical analysis
A sample size of approximately 200 patients (98 per
study treatment) would provide 90 % power to claim
noninferiority between groups for prealbumin at Day 5.
The primary comparison was that OLIVE was not infer-
ior to the SOYBEAN in maintaining or increasing serum
prealbumin levels. In the sample size calculation, it was
assumed that the true ratio was 1, the coefficient of vari-
ance (CV) was 0.5, and the non-inferiority margin was
−20 %. These assumptions resulted in a sample size of
98 patients per study treatment. It was decided to enroll
at least 200 patients per treatment group with an evalu-
able primary endpoint to generate additional clinical
data for this study. The sample size was calculated by
PASS version 2011. Approximately 500 subjects were
randomized to achieve 400 subjects who had efficacy as-
sessments on Day 5, assuming up to 20 % of randomized
subjects would drop out of the study before the Day 5
assessments.
The primary comparison was that OLIVE is not inferior
to SOYBEAN in maintaining or increasing serum prealbu-
min levels. Noninferiority was claimed if the anti-log of
the lower bound of the 95 % confidence interval (CI) of
the treatment difference was at least 0.80.
Analyses were performed on the intention-to-treat
population (ITT), defined as all patients randomized.
The primary efficacy analyses were based on the modi-
fied intention-to-treat (mITT) population, defined as all
ITT patients who received study treatment and provided
some efficacy data. The per protocol (PP) population
was defined as the subset of ITT patients who had no
major protocol violations and had Day 5 efficacy data.
All safety analyses were conducted on the safety popula-
tion, defined as all patients who received any amount of
study treatment.
Unless otherwise stated, all statistical analyses were
performed using a two-sided hypothesis test at the 5 %
level of significance. No adjustment for Type I error rate
was required for the analysis of the primary endpoint be-
cause the study had only one primary endpoint with one
comparison. Due to the large sample size there was no
need to test the model assumptions (ie, normality test).
The primary efficacy variable was the serum prealbu-
min level at Day 5. The log transformed primary efficacy
variable was analyzed via an analysis of covariance
(ANCOVA) model with treatment and study site as the
main effects and baseline serum prealbumin as the co-
variate. The least square (LS) mean ± standard deviation
(SD) estimates of the treatment effects for OLIVE and
the control, as well as the two-sided 95 % CI of the geo-
metric mean ratio of test/control was derived.
Preparation time of study treatment (Days 1 to 5) and
length of hospitalization were summarized by treatment
group. Differences between treatment groups were ana-
lyzed using Kruskal-Wallis test. Time to achieve toler-
ability of oral nutrition was summarized using the
Kaplan-Meier method and compared using a log-rank
test. Other secondary efficacy variables were analyzed
the same way as the primary variable with change from
baseline and ANCOVA model on log-scale with baseline
as covariate and treatment and study site as main effects.
Injection site rating by the Investigator was analyzed
using the Cochran-Mantel-Haenszel test with modified
ridit scores.
For the safety analyses, statistical comparisons were
performed between the two treatment groups. Continu-
ous data were compared using an ANOVA and categor-
ical data were compared using a Chi-square test/Fisher's
exact test. AE relationship and severity were compared
using Cochran-Mantel-Haenszel test with modified ridit
scores. AEs were coded according to the Medical Dic-
tionary for Regulatory Activities (MedDRA).
All statistical analyses were completed using SAS ver-
sion 9.2 (SAS Institute Inc, Cary, North Carolina USA).
Results
Patient disposition
A total of 480 patients consented (Fig. 1) and 458
patients were enrolled and randomized into the study.
All randomized patients were included in the ITT popu-
lation, 226 (100.0 %) patients in the OLIVE group and
232 (100.0 %) patients in the SOYBEAN group. The
safety population comprised 222 (98.2 %) patients in the
OLIVE group and 231 (99.6 %) patients in the SOY-
BEAN group. The mITT population comprised 219
(96.9 %) patients in the OLIVE group and 224 (96.6 %)
patients in the SOYBEAN group. The PP population
comprised 183 (81.4 %) patients in the OLIVE group
and 190 (81.9 %) in the SOYBEAN group. Similar
Jia et al. Nutrition Journal  (2015) 14:119 Page 4 of 15
percentages of patients discontinued from the study
in the OLIVE group (8.8 %) and the SOYBEAN group
(10.3 %). The main reasons for discontinuation in
both groups were patient withdrew consent and AEs
(Fig. 1).
Demographic and baseline clinical characteristics
The demographic and baseline clinical characteristics of
patients in the OLIVE and the SOYBEAN groups (ITT
population) were not different (Table 1). Most patients
were male (61 %, 279/458), identified as Chinese Han
(95 %, 436/458), and had a mean age of 56 years. Most
patients underwent surgery and experienced high com-
plexity surgery (62 %, 283/458) with a mean duration of
3 h.
Nutritional intakes
Treatment exposure and doses administered were simi-
lar between the treatment groups. The mean ± SD dura-
tions of study treatment exposure were 8.4 ± 3.7 days in
the OLIVE group and 8.2 ± 3.7 days in the SOYBEAN
group. The mean ± SD doses administered were 16761.0
± 7086.8 mL in the OLIVE group and 16877.5 ±
7453.0 mL in the SOYBEAN group. There were no sta-
tistically significant differences in the mean ± SD flow
rate, total volume prescribed, total volume administered,
volume ratio (prescribed/administered volume), total
duration prescribed, total duration administered, or dur-
ation ratio (prescribed/administered duration) between
the treatment groups (data not shown). There was no
statistically significant difference between the time to
Figure 1 Patient disposition flowchart
Table 1 Patient Demographics and Baseline Characteristics of






Sex, n (%) 0.482
Male 134 (59.3) 145 (62.5)
Female 92 (40.7) 87 (37.5)
Race, n (%) 0.673
Chinese Han 216 (95.6) 220 (94.8)
Chinese other minority 8 (3.5) 11 (4.7)
Other 2 (0.9) 1 (0.4)
Age, years, mean ± SD 55.8 ± 13.1 56.3 ± 11.7 0.656
BMI, kg/m2, mean ± SD 21.7 ± 3.9a 21.8 ± 3.9b 0.667
Underwent surgery, n (%) 195 (86.3) 202 (87.1) 0.805
Complexity of surgeryc, n (%) 0.859
Medium complexity 49 (21.7) 48 (20.7)
High complexity 140 (61.9) 143 (61.6)
Missing 37 (16.4) 41 (17.7)
Duration of surgery, hours, mean ± SD 2.9 ± 1.3 3.0 ± 1.4 0.645
Abbreviations: BMI body mass index, SD standard deviation
an = 217
bn = 226
cComplexity of surgery was determined by the investigator based on patient
and surgical characteristics
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achieve adequate enteral intake (following 5 days of PN)
for the OLIVE group and the SOYBEAN group (median
time: OLIVE 2.0 days versus SOYBEAN 2.0 days; log
rank P = 0.786).
Anabolic/catabolic endpoints
OLIVE was noninferior to SOYBEAN in maintaining or
increasing serum prealbumin levels at Day 5 in the
mITT population (LSGM ratio and [95 % CI] 1.12
[1.06, 1.19]; P = 0.0002) and the PP population (LSGM
and [95 % CI] 1.12 [1.05, 1.19], P = 0.0006) (Fig. 2). This
observation was consistent in the subgroup analyses of
age, gender, no surgery, surgery of medium complexity,
and surgery of high complexity (Fig. 2).
Serum prealbumin levels and serum albumin levels were
significantly higher in the OLIVE group compared with the
SOYBEAN group at Day 5 (Table 2). Prealbumin and albu-
min increased in the OLIVE group and decreased in the
SOYBEAN group. No significant difference in serum IGF-I
levels were observed between the treatment groups at Day
5; however, at end of therapy (EOT)/Day 14, serum IGF-I
levels were significantly higher in the OLIVE group com-
pared with the SOYBEAN group. No significant between-
group differences were observed in the 6-h urinary urea
nitrogen and 6-h urinary excretion of 3-methylhistidine
(Table 2).
Lipid endpoints
Significant increases in serum oleic acid levels were ob-
served for both treatment groups; however, the increases
in the OLIVE group were greater than those observed in
the SOYBEAN group (Table 3). No statistically signifi-
cant differences in serum levels of linoleic acid, arachi-
donic acid, and EPA were observed between treatment
groups at any timepoint (Table 3).
Inflammation, oxidation, and infections
There was a very small but significant difference at Day
5 in the serum levels of IL-6 observed between the
OLIVE and the SOYBEAN groups (Table 4). In both
groups, IL-6 levels decreased. No significant differences
in the serum levels of cortisol, procalcitonin, CRP, or
ICAM-1 were observed between treatment groups. No
significant differences in the serum levels of malondial-
dehyde or F2-isoprostane were observed at Day 5 or
EOT/Day 14 (Table 4).
Significantly more patients in the SOYBEAN group
(10.4 % [24/231]) than the OLIVE group (3.6 % [8/
222]) experienced an infection or infestation (Table 5).
Overall, the frequency of infections in the study was
low (7.1 % [32/453]). The most common infections
were lung infections, which were higher in the SOY-
BEAN group. The second most common infection
was incision/wound infections. Bloodstream infections
were not reported to occur in the study.
Preparation time
The preparation time for study treatment was signifi-
cantly less for OLIVE compared with the SOYBEAN on
all days assessed (P <0.001 for all values [Fig. 3]).
Hospital time and mortality
There were no significant differences between the
OLIVE group and the SOYBEAN group for the length
of hospitalization from admission to discharge or for the
length of hospitalization from randomization to
discharge (Table 6). Five patients died during the study;
one patient in the OLIVE group (cardiopulmonary fail-
ure) and four patients in the SOYBEAN group (severe
pharyngeal hemorrhage, severe abdominal infection,




Overall, the safety and tolerability profile of OLIVE was
similar to SOYBEAN. The most common treatment-
emergent AEs (TEAEs) occurring in greater than 5 % of
Figure 2 OLIVE efficacy in the modified intention-to-treat population and prespecified subgroups. Mean ± SD prealbumin levels on Day 5. LSGM
ratio and 95 % CI for the comparison of OLIVE versus SOYBEAN. The LSGM ratio is the antilog of (log (GM) ± 1.96SE). The P value for group difference
was adjusted for baseline values and study sites. Abbreviations: CI confidence interval, LSGM least square geometric means, mITT modified intention-to-
treat, PN parenteral nutrition, SD standard deviation, SE standard error
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patients in both groups were pyrexia and infusion site
swelling (Table 7). Discontinuations from the study were
low, with seven patients in the OLIVE group and nine
patients in the SOYBEAN group discontinuing from the
study due to AEs.
There were no differences between groups in the
severity of TEAEs (P = 0.073) or in the relationship of
TEAEs to study treatment (P = 0.393) as considered
by the Investigators. Most TEAEs were considered to
be mild in severity in both the OLIVE group (77.6 %
[125/222] patients) and the SOYBEAN group (69.8 %
[118/231] patients). Severe TEAEs were reported in 2/
222 (1.2 %) patients in the OLIVE group and 10/231
(5.9 %) patients in the SOYBEAN group. The severe
TEAEs reported by the two patients in the OLIVE
group were cardiopulmonary failure and acute myo-
cardial infarction. The severe TEAEs reported by the
ten patients in the SOYBEAN group were epistaxis,
Table 2 Effects of OLIVE and SOYBEAN on Markers of Nutrition in Patients Receiving Parenteral Nutrition
Nutrition Marker OLIVE SOYBEAN OLIVE vs SOYBEAN
Visit N Mean ± SD N Mean ± SD LSGM Ratio (95 % CI) P-value
Albumin (g/L) Baseline 214 33.11 ± 5.75 220 33.23 ± 5.84 .
Day 5 211 34.02 ± 5.32 216 32.93 ± 5.15 1.04 (1.01, 1.07) 0.0139
EOT/Day 14 82 35.37 ± 5.86 78 35.55 ± 5.3 1 (0.96, 1.05) 0.9393
Prealbumin (mg/dL) Baseline 213 15.08 ± 4.64 219 15.15 ± 5.01 .
Day 5 217 15.66 ± 5.12 218 13.95 ± 5.05 1.12 (1.06, 1.19) 0.0002
EOT/Day 14 210 17.24 ± 6.82 219 15.15 ± 6.37 1.16 (1.08, 1.24) 0.0001
Prealbumin (PP) (mg/dL) Baseline 182 14.82 ± 4.58 188 14.97 ± 5.02 .
Day 5 184 15.7 ± 5.01 190 14.19 ± 5.06 1.12 (1.05, 1.19) 0.0006
EOT/Day 14 184 17.38 ± 6.96 193 15.37 ± 6.43 1.16 (1.07, 1.25) 0.0002
IGF-I (ug/L) Baseline 214 107.31 ± 49.61 220 110.9 ± 55.34 .
Day 5 211 125.81 ± 64.35 218 121.15 ± 61.11 1.04 (0.96, 1.13) 0.3437
EOT/Day 14 82 142.9 ± 70.16 78 125.27 ± 65.22 1.16 (1, 1.35) 0.045
6-h urea nitrogen, urine (mmol/L) Baseline 211 124.02 ± 92.1 218 129.39 ± 78.47 .
Day 5 211 141.95 ± 100.85 216 151.82 ± 98.15 0.91 (0.8, 1.03) 0.1271
EOT/Day 14 81 150.4 ± 100.19 76 144 ± 101.81 1 (0.82, 1.23) 0.9797
6-h 3-Methylthistidine, urine (ug/mL) Baseline 211 1.32 ± 2.61 217 1.37 ± 1.56 .
Day 5 212 1.44 ± 4.29 216 1.11 ± 0.98 1.02 (0.9, 1.14) 0.7791
EOT/Day 14 81 1.98 ± 2.18 77 1.74 ± 4.4 1.1 (0.87, 1.38) 0.4224
Abbreviations: CI confidence interval, EOT end of therapy, IGF-I insulin-like growth factor-I, LSGM least square geometric mean, PP per protocol, SD standard deviation
Table 3 Effects of OLIVE and SOYBEAN on Serum Free Fatty Acid Levels in Patients Receiving Parenteral Nutrition
Free Fatty Acid OLIVE SOYBEAN OLIVE vs SOYBEAN
Visit N Mean ± SD N Mean ± SD LSGM Ratio (95 % CI) P-value
Arachidonic Acid (ng/mL) Baseline 214 2582.36 ± 1628.43 219 2435.61 ± 1691.17 .
Day 5 211 1647.86 ± 1169.39 217 1657.64 ± 1109.07 0.96 (0.83, 1.1) 0.5511
EOT/Day 14 82 1907.33 ± 1503.86 78 2061.49 ± 1368.59 0.82 (0.64, 1.06) 0.127
Eicosapentaenoic Acid (ng/mL) Baseline 214 6238.86 ± 10452.35 219 5162.16 ± 3904.17 .
Day 5 211 5492.24 ± 4259.41 217 5490.93 ± 3916.9 1.05 (0.91, 1.21) 0.5148
EOT/Day 14 82 5604.48 ± 5433.61 78 4451.74 ± 3218.58 1.04 (0.75, 1.43) 0.8314
Linoleic Acid (ng/mL) Baseline 214 114371.89 ± 81968.03 219 106834.77 ± 74014.98 .
Day 5 211 122618.72 ± 74778.06 217 138023.51 ± 84529.99 0.89 (0.77, 1.04) 0.1543
EOT/Day 14 82 120846.77 ± 101009.54 78 122106.26 ± 73206.47 0.76 (0.53, 1.09) 0.1369
Oleic Acid (ng/mL) Baseline 214 70758.12 ± 85210.57 219 63562.45 ± 44727.06 .
Day 5 211 85697.52 ± 52610.19 217 71773.72 ± 45452.38 1.22 (1.09, 1.37) 0.0006
EOT/Day 14 82 81704.84 ± 58732.76 78 63696.58 ± 45050 1.11 (0.81, 1.51) 0.517
Abbreviations: CI confidence interval, EOT end of therapy, LSGM least square geometric mean, SD standard deviation
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pharyngeal hemorrhage, urinary tract infection, ab-
dominal infection, hypovolemic shock, lung infection,
pyrexia, hypokalemia, hypernatremia, ureteric fistula,
renal failure acute, vomiting, and intestinal fistula.
Eight patients in the OLIVE group and 14 patients
in the SOYBEAN group experienced serious AEs
(SAEs). Overall, each SAE was reported by ≤1.1 % of
patients. All reported SAEs were considered by the
Table 4 Effects of OLIVE and SOYBEAN on Markers of Inflammation and Infections in Patients Receiving Parenteral Nutrition
Marker OLIVE SOYBEAN OLIVE vs SOYBEAN
Visit N Mean ± SD N Mean ± SD LSGM Ratio (95 % CI) P-value
Cortisol (nmol/L) Baseline 214 492.98 ± 284.67 219 499.61 ± 256.24 .
Day 5 212 371.97 ± 145.68 218 362.98 ± 130.29 1.02 (0.95, 1.1) 0.5677
EOT/Day 14 82 382.37 ± 193.88 78 395.31 ± 155.08 0.9 (0.77, 1.04) 0.1617
C-Reactive protein (mg/L) Baseline 214 54.56 ± 54.46 220 56 ± 51.13 .
Day 5 211 42.33 ± 42.9 216 47.17 ± 42.98 0.95 (0.81, 1.12) 0.5503
EOT/Day 14 82 20.95 ± 34.44 78 21.92 ± 31.23 0.9 (0.62, 1.31) 0.5785
Procalcitonin (ng/mL) Baseline 214 0.91 ± 1.84 219 1.19 ± 2.67 .
Day 5 212 0.36 ± 0.97 218 0.44 ± 1.29 0.98 (0.86, 1.11) 0.717
EOT/Day 14 82 0.15 ± 0.2 78 0.28 ± 1.1 0.88 (0.71, 1.11) 0.283
sICAM-1 (ug/L) Baseline 214 264.37 ± 127 220 260.97 ± 128.62 .
Day 5 209 321.56 ± 158.86 217 304.41 ± 154.53 1.02 (0.94, 1.1) 0.6462
EOT/Day 14 81 337.84 ± 152.58 78 352.73 ± 197.27 0.96 (0.85, 1.08) 0.4683
Interleukin-6 (ng/L) Baseline 214 143.03 ± 271.46 220 191.72 ± 705.37 .
Day 5 211 19.63 ± 57.58 218 20.11 ± 44.19 0.82 (0.69, 0.96) 0.0173
EOT/Day 14 ND ND ND ND ND ND
Malondialdehyde (nmol/L) Baseline 214 12.46 ± 25.2 219 11.4 ± 21.93 .
Day 5 211 13.57 ± 27.65 217 12.49 ± 23.13 0.97 (0.87, 1.08) 0.5865
EOT or Day 14 82 12.65 ± 27.81 78 10.77 ± 21.68 0.86 (0.71, 1.04) 0.115
F2-Isoprostane (ng/mL) Baseline 214 0.13 ± 0.17 219 0.11 ± 0.14 .
Day 5 211 0.19 ± 0.33 217 0.14 ± 0.2 1.13 (0.85, 1.5) 0.4006
EOT/Day 14 82 0.16 ± 0.21 78 0.18 ± 0.29 0.9 (0.58, 1.4) 0.6502
Abbreviations: CI confidence interval, EOT end of therapy, LSGM least square geometric mean, ND not detected, SD standard deviation, sICAM serum intercellular
adhesion molecule-1
Table 5 Treatment Emergent Infections




Total infections 8 26*
Total patients infected 8 (3.6 %) 24*
(10.4 %)
Lung infections 2 13*
Incision/wound site infections 5 3
Urinary tract infections 1 2
Abdominal/gastrointestinal infections 0 2
Scrotal infections 0 1



























Figure 3 Preparation time of study treatment (Day 1 through Day 5).
*P <0.05 by Kruskal-Wallis. Error bars indicate standard deviations
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Investigator to be not associated or unlikely to be
related to the study treatment. Most SAEs were
considered by the Investigator to be moderate or
severe and recovered/resolved with no sequelae by
the end of the study.
Systemic safety
Alanine aminotransferase and aspartate aminotransferase
were higher in the SOYBEAN group at baseline (Table 8).
There were no statistically significant differences between
groups at Day 5 or EOT/Day 14 and mean values were
within normal limits or only slightly above the normal
range. However, when analyzed for change from baseline,
alanine aminotransferase was significantly different be-
tween groups at Day 5 and EOT/Day 14, whereas aspartate
aminotransferase was not significantly different between
groups. Alkaline phosphatase was similar between groups
at baseline. Levels were significantly different between
groups at Day 5 but not at EOT/Day 14. Most values were
within normal ranges. Gamma-glutamyltransferase was
within normal limits for most patients and similar between
groups at baseline. When analyzed by change from base-
line, gamma-glutamyltransferease values were higher in the
OLIVE group than in the SOYBEAN group at Day 5, but
not at EOT/Day 14. Total bilirubin was similar between
groups at all time points. Blood urea nitrogen was similar
between groups at baseline. When analyzed by change from
baseline, blood urea nitrogen values were higher in the
OLIVE group at Day 5 but not at EOT/Day 14. Most values
remained within normal limits throughout the study.
Table 6 Effects of OLIVE and SOYBEAN on Hospital Time in Patients Receiving Parenteral Nutrition
Length of Hospitalization OLIVE SOYBEAN OLIVE vs SOYBEAN
N Mean ± SD Median N Mean ± SD Median P-value
From admission to discharge, days 219 16.92 ± 4.99 16 224 18.1 ± 8.65 16 0.7823
From randomization to discharge, days 219 10.84 ± 4.27 10 224 12.04 ± 7.82 10 0.4854
Abbreviations: SD standard deviation
Table 7 Study Drug-Related Adverse Events in the Safety Population
System Organ Class Preferred Term OLIVE SOYBEAN
Frequencya n (%)b Frequencya n (%)b
General disorders and administration site conditions 164 85 (38.3) 157 89 (38.5)
Swelling 60 19 (8.6) 50 17 (7.4)
Pyrexia 38 33 (14.9) 40 35 (15.2)
Infusion site swelling 20 16 (7.2) 26 24 (10.4)
Gastrointestinal disorders 65 43 (19.4) 72 50 (21.6)
Nausea 22 17 (7.7) 19 17 (7.4)
Vascular disorders 47 33 (14.9) 65 41 (17.7)
Phlebitis 24 12 (5.4) 31 12 (5.2)
Peripheral vascular disorder 14 13 (5.9) 23 22 (9.5)
Metabolism and nutrition disorders 35 28 (12.6) 60 42 (18.2)
Hypokalemia 3 3 (1.4) 18 18 (7.8)
Investigations 41 27 (12.2) 38 26 (11.3)
Gamma-glutamyltransferase increased 11 11 (5.0) 7 7 (3.0)
Injury, poisoning and procedural complications 44 27 (12.2) 30 25 (10.8)
Procedural pain 21 12 (5.4) 9 7 (3.0)
Incision site pain 16 12 (5.4) 12 10 (4.3)
Respiratory, thoracic and mediastinal disorders 31 23 (10.4) 26 20 (8.7)
Productive cough 14 14 (6.3) 11 11 (4.8)
Cough 11 11 (5.0) 11 11 (4.8)
Infections and infestations 8 8 (3.6) 26 24 (10.4)
Hepatobiliary disorder 13 13 (5.9) 7 7 (3.0)
aNumber of events
bNumber and percentage of patients with at least one event
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Creatinine remained normal in both groups throughout the
study; there were no differences between groups.
For the change from baseline in serum electrolytes,
statistically significant differences in chloride (Day 5 and
EOT/Day 14), phosphorus (Day 5 and EOT/Day 14), and
potassium (Day 5 and EOT/Day 14) were observed
(Table 8). Bicarbonate, chloride, phosphorus, potassium,
and sodium levels were within normal limits in both treat-
ment groups at Day 5 and EOT/Day 14.
Cholesterol increased more in the OLIVE group com-
pared to the SOYBEAN group, but values remained
within normal limits in most patients (Table 8). Trigly-
ceride levels increased in both groups, reflecting the tri-
glyceride content of the lipid emulsions. Values were
Table 8 Absolute Serum Chemistry Measures in the Modified Intention to Treat Population
Serum Chemistry Measure OLIVE SOYBEAN OLIVE vs SOYBEAN
Visit N Mean ± SD N Mean ± SD LS Mean ± SE (95 % CI) P-value
Alanine aminotransferase, U/L Baseline 212 41.4 ± 87.15 216 73.3 ± 197.14
Day 5 79 31.0 ± 27.86 85 29.2 ± 55.41 21.3 ± 6.89 (7.7, 34.9) 0.002
EOT/Day 14 201 48.8 ± 61.23 196 38.5 ± 38.70 42.5 ± 15.24 (12.5, 72.5) 0.006
Alkaline phosphatase, U/L Baseline 210 72.5 ± 46.87 212 71.7 ± 35.65
Day 5 79 87.7 ± 58.27 85 74.7 ± 40.41 18.8 ± 5.65 (7.7, 30.0) 0.001
EOT/Day 14 201 123 ± 96.24 196 106.9 ± 70.89 11.6 ± 7.72 (−3.6, 26.8) 0.133
Aspartate aminotransferase, U/L Baseline 210 52.8 ± 117.38 212 72.3 ± 191.38
Day 5 79 31.9 ± 19.27 85 22.6 ± 15.82 22.4 ± 8.87 (4.9, 40.0) 0.12
EOT/Day 14 201 35.8 ± 39.42 196 30.6 ± 35.13 25.5 ± 17.25 (−8.5, 59.4) 0.141
γ-Glutamyltransferase, U/L Baseline 210 39.2 ± 74.63 212 42.7 ± 70.32
Day 5 79 100.5 ± 136.62 85 68.9 ± 71.69 34.9 ± 11.96 (11.3, 58.5) 0.004
EOT/Day 14 201 139.2 ± 165.89 196 118.1 ± 140.65 12.4 ± 13.45 (−14.1, 38.8) 0.358
Total bilirubin, μmol/L Baseline 212 18.00 ± 15.98 216 16.12 ± 10.69
Day 5 79 13.21 ± 9.76 85 11.86 ± 9.56 −0.39 ± 1.50 (−3.35, 2.56) 0.793
EOT/Day 14 201 12.86 ± 9.34 196 13.87 ± 18.94 −2.97 ± 1.42 (−5.76, −0.19) 0.36
Blood urea nitrogen, mmol/L Baseline 212 3.63 ± 2.07 216 3.88 ± 1.91
Day 5 85 4.21 ± 2.51 92 4.35 ± 2.71 0.51 ± 0.24 (0.03, 0.99) 0.039
EOT/Day 14 200 5.23 ± 2.47 195 4.93 ± 2.27 0.38 ± 0.21 (−0.03, 0.79) 0.072
Creatinine, μmol/L Baseline 212 67.8 ± 23.6 218 67.4 ± 21.1
Day 7 110 62.0 ± 15.8 112 60.2 ± 17.4 −2.3 ± 2.7 (–7.5, 3.0) 0.40
EOT/Day 14 200 62.6 ± 16.5 195 62.2 ± 16.7 −0.7 ± 1.7 (-4.1, 2.7) 0.69
Chloride, mmol/L Baseline 212 104.4 ± 4.33 216 103.7 ± 4.39
Day 5 85 101.4 ± 3.55 93 102.4 ± 4.53 −1.6 ± 0.73 (−3.1, −0.2) 0.027
EOT/Day 14 200 101.0 ± 3.55 194 101.8 ± 5.03 −1.3 ± 0.59 (−2.5, −0.1) 0.030
Phosphorus, mmol/L Baseline 155 1.07 ± 0.26 162 1.15 ± 0.79
Day 5 83 1.21 ± 0.47 89 0.98 ± 0.45 0.25 ± 0.09 (0.09, 0.42) 0.003
EOT/Day 14 183 1.26 ± 0.21 176 1.20 ± 0.32 0.17 ± 0.08 (0.00, 0.34) 0.044
Potassium, mmol/L Baseline 212 4.58 ± 9.07 216 3.98 ± 0.47
Day 5 85 4.35 ± 0.57 93 3.95 ± 0.53 0.43 ± 0.10 (0.23, 0.63) <0.001
EOT/Day 14 201 4.97 ± 9.16 194 4.06 ± 0.53 0.28 ± 0.06 (0.15, 0.40) <0.001
Total cholesterol, mmol/L Baseline 206 3.52 ± 0.95 210 3.60 ± 0.89
Day 5 77 3.48 ± 0.96 84 7.60 ± 38.15 −4.35 (−13.47, 4.77) 0.348
EOT/Day 14 196 3.76 ± 0.90 188 3.6 ± 0.94 0.20 (0.02, 0.39) 0.029
Triglycerides, mmol/L Baseline 206 0.89 ± 0.53 211 0.91 ± 0.58
Day 5 77 1.89 ± 0.95 85 1.51 ± 0.68 0.41 (0.19, 0.63) <0.001
EOT/Day 14 200 1.72 ± 0.88 193 1.50 ± 0.67 0.25 (0.09, 0.40) 0.002
Abbreviations: CI confidence interval, EOT end of treatment, LS least squares, SD standard deviation, SE standard error
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slightly, but significantly higher in the OLIVE group
compared to the SOYBEAN group. No patient withdrew
from the study due to lipid abnormalities (ie, elevated
cholesterol or triglycerides) and none of the PN infu-
sions required adjustment for lipid levels.
No statistically significant differences (all P >0.05) be-
tween the OLIVE group and SOYBEAN group were ob-
served for serum glucose or insulin use (Table 9). In
addition, there were no significant differences between
groups for insulin levels in the blood or hematological
measures (basophils, neutrophils, eosinophils, lympho-
cytes, monocytes, platelets, hemoglobin, and hematocrit).
Absolute counts for basophils, eosinophils, lymphocytes,
monocytes, and neutrophils remained within normal
ranges in both treatment groups (data not shown).
Discussion
This is the largest prospective, randomized, open-label,
controlled, multi-center study to date that compares two
lipid emulsions used as part of complete PN; an olive
oil-based lipid emulsion PN regimen and a soybean oil-
based lipid emulsion PN regimen. Overall, OLIVE was
not inferior to SOYBEAN for prealbumin levels, im-
proved the anabolic/catabolic status of patients enrolled
in the study, and was well tolerated compared with SOY-
BEAN. The improvement in anabolic status for the
OLIVE group was indicated by higher levels of the pro-
tein endpoints of prealbumin, albumin, and IGF-1. The
lack of difference in urinary excretion of urea and 3-
methylhistidine between the groups suggests that catab-
olism was similar in each group. CRP, ICAM-1, procalci-
tonin, and oxidation were similar in each group, but
infections were significantly lower with OLIVE. Oleic
acid levels increased with OLIVE; but linoleic acid, ara-
chidonic acid, and EPA were similar between groups.
OLIVE was associated with shorter preparation times
compared with the compounded SOYBEAN admixture.
Prealbumin was chosen as the primary endpoint for
the study following discussion with a number of experts.
Serum prealbumin levels are determined by a variety of
factors, including synthesis, degradation, and tissue dis-
tribution. Synthesis is dependent upon supply of amino
acids to the liver and activation of prealbumin synthetic
pathways. During metabolic stress, as occurs with illness
and surgery, activation of inflammatory pathways (espe-
cially IL-6) increase prealbumin degradation, limit it’s
synthesis, and may increase tissue distribution by leak-
age into tissues (increased vascular permeability) [17].
Lipid emulsions and other components of PN have been
shown to modulate endothelial permeability, inflamma-
tion, anabolism, catabolism, and immune cell functions
[18]. As a result, prealbumin was thought to be a com-
posite indicator of amino acid supply, protein synthetic
capacity, catabolism, and inflammation. All of these end-
points are important targets for nutrition support and
were assessed in this study. Anabolism was assessed with
prealbumin, albumin, and IGF-1 levels; catabolism was
assessed with nitrogen excretion and 3-methylhistidine
excretion. In addition, we also assessed other endpoints
that included infections, hospital stay, morbidities (AEs),
mortality, organ function (renal, hepatic, hematologic),
and metabolic status (oxidation, fatty acids, cholesterol,
triglycerides, glucose, insulin, electrolytes).
OLIVE was associated with significant increases in
prealbumin, albumin, and IGF-I compared with SOY-
BEAN. As no difference between groups for catabolic
markers were noted, these results would suggest that the
effects of OLIVE are likely to be mediated by anabolism.
IGF-I is particularly sensitive to protein intake and re-
sponds rapidly to protein energy status [19]. This is the
first study to compare the effects of an olive oil-based
PN regimen with a soybean oil-based PN regimen on
serum IGF-I levels. While numerous studies have re-
ported the positive nutritional effects of OLIVE on one
or perhaps two nutritional markers [8, 20–22], this is
the first study to examine both anabolic and catabolic
marker profiles and one of the first studies to demon-
strate that OLIVE is effective in increasing anabolism in
critically ill patients. The exact mechanism for the differ-
ences in anabolism are unclear, but may relate to the
high ω-6 PUFA levels in the SOYBEAN versus OLIVE
emulsion that may exacerbate the inflammatory re-
sponse to surgery and illness.
The physiologic response to injury is an acute phase
reaction (APR) mediated by a sudden increase in cortisol
and the production of proteins such as CRP and
cytokines (IL-1, IL-6, tumor necrosis factor-α [TNFα]).
APR proteins have direct effects on catabolism and
Table 9 Serum Glucose Concentrations (mmol/L) and Insulin Usea
n OLIVE Mean ± SD n SOYBEAN Mean ± SD P-value (change from baseline between groups)
Baseline 212 7.1 ± 2.3 216 7.2 ± 2.3
Day 3 207 8.6 ± 3.1 218 8.4 ± 3.5 0.74
Day 7 110 6.7 ± 2.6 112 7.0 ± 2.7 0.13
EOT or Day 14 201 6.3 ± 2.2 193 6.9 ± 3.0 0.09
Patients requiring insulin 41 (18.5 %) – 48 (20.8 %) –
aValues are not significantly different at any time point; Abbreviations: EOT end of treatment, SD standard deviation
Jia et al. Nutrition Journal  (2015) 14:119 Page 11 of 15
inflammatory pathways and, therefore, play a role in nu-
tritional status, particularly in critically ill patients where
malnutrition and systemic inflammation coexist [19].
Both OLIVE and SOYBEAN were associated with de-
creases in cortisol, CRP, and IL-6 levels. The effects of
OLIVE and SOYBEAN on APR proteins were consistent
with a prior smaller study that showed both lipid formu-
lations were associated with decreases in CRP and TNFα
[21]. Prior studies have also shown that OLIVE signifi-
cantly lowers IL-6 levels compared with a medium chain
triglyceride/long chain triglyceride (MCT/LCT) lipid
emulsion, but no between-group differences in IL-6 were
noted in two studies that compared OLIVE with SOY-
BEAN [14, 21, 23]. A limited number of acute phase
proteins (ie, CRP, IL-6, procalcitonin, ICAM-1, cortisol)
were assessed in this study and no differences between
levels were observed. Oxidative markers (ie, MDA, F2-
isoprostane) were also measured and no differences were
found. It is possible that more frequent sampling, meas-
urement of tissue levels rather than blood levels, or
measurement of other markers (ie, leukocyte functions)
may have shown differences between lipid groups.
SOYBEAN lipid emulsion contains high levels (ap-
proximately 54 %) of the ω-6 PUFA, linoleic acid, while
OLIVE contains much lower levels (approximately
18 %). It has been hypothesized that the high levels of
linoleic acid in SOYBEAN exacerbate inflammation
[15, 16, 18, 24, 25] in patients undergoing acute ill-
ness and tissue injury (such as major surgery). How-
ever, we were unable to detect such exacerbation in
this study using conventional inflammatory markers
such as cortisol, IL-6, ICAM-1, CRP, and procalcito-
nin. It is possible that other inflammatory markers
(such as leukotrienes) may have been higher in the
SOYBEAN group than in the OLIVE group.
Small studies directly comparing olive oil-based lipid
emulsions with soybean oil-based lipid emulsions have
provided conflicting results, with some studies showing
significant reductions in inflammatory and oxidative
stress markers [23], while other studies have reported no
differences in inflammatory or oxidative stress markers
between olive oil-based PN and soybean oil-based PN ad-
mixtures [14, 21]. Furukawa and colleagues [12] investi-
gated the impact that the degree of stress associated with
surgery had on IL-6 production in patients receiving
lipid-free or soybean oil-based PN admixtures. The re-
sults of their study showed that soybean oil-based PN
significantly increased IL-6 levels in patients experiencing
severe stress, but not in patients experiencing moderate
stress. Several reasons may account for the differences
between prior studies and this study including sample
size, differences in the patient populations between the
studies, or differences in the level of stress the patients
were experiencing.
Measurement of lipids and lipid upper derivatives re-
vealed changes in the levels of fatty acid moieties that
were consistent with the lipid source contained in the
two PN regimens. Not surprisingly, linoleic acid levels
increased in both treatment groups, albeit it to a lesser
extent in the OLIVE group. Despite the trend for in-
creased linoleic acid in the SOYBEAN group, arachi-
donic acid levels decreased similarly in both groups.
Thus, supply of larger amounts of linoleic acid with
SOYBEAN had no effect upon circulating arachidonic
acid levels. The decrease in arachidonic acid levels in
both groups suggests that it was being consumed as sub-
strate for the APR. It is important to note that tissue
levels of these fatty acids, not measured in this study,
may better reflect cellular effects of the fatty acids. Simi-
larly, the significantly greater increase in oleic acid ob-
served in the OLIVE group compared with the
SOYBEAN group is consistent with the olive oil con-
tained in OLIVE. Cholesterol and triglycerides are com-
ponents of the lipid emulsions used in both groups.
Cholesterol increased to a greater extent in the OLIVE
group; however, differences in levels were small and un-
likely to have clinical significance. Cholesterol levels
remained within normal limits (ie, <5.2 mmol/L) in most
patients. Triglyceride levels increased in both study
groups, reflecting the infusion of triglycerides in the lipid
emulsions. Levels increased slightly but significantly
more in the OLIVE group. Most levels remained below
the upper recommended triglyceride level for parenteral
nutrition (ie, 3.5–4.5 mmol/L). The greater increase in
triglycerides in the OLIVE group likely reflects the
slightly slower clearance of olive oil-based triglycerides
compared to soybean triglycerides.
One of the most clinically relevant findings of this
study was the decreased incidence of infections in the
OLIVE group compared to the SOYBEAN group. There
were many similarities between the two groups including
rate and complexity of surgery, duration of stay in
hospital, duration of PN, and glucose levels. Therefore,
these factors do not explain the difference in infection
rate.
Studies comparing compounded PN with multi-
chamber PN have shown that compounded PN is associ-
ated with a higher rate of bloodstream infections [26].
However, in this study we did not see a difference in
blood stream infections between groups, as most infec-
tions were of pulmonary origin followed by incision site
infections and urinary tract infections. Small studies
have also reported that the use of soybean oil-based lipid
emulsions is associated with an increased risk of infec-
tions [15]. This effect is believed to be a result of the
proinflammatory and immunosuppressive effects of the
high linoleic acid content of soybean oil-based emulsions
[15, 16, 27]. However, it should be noted that the overall
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rate of infections in this study was low, as is typically
seen in elective surgery populations. Historically, infec-
tion rates in patients receiving total PN have been much
higher. Prior studies have suggested that lipid emulsions
that are high in oleic acid may have less impact on the
immune system compared with soybean oil-based lipid
emulsions [15, 17, 28, 29]. In contrast, a recent study
comparing SOYBEAN with OLIVE reported that there
were no differences in immune cell functions in 100 in-
tensive care unit (ICU) patients [21]. Thus, the causes or
mechanisms responsible for the different incidences of
infection between groups remains unclear.
Manzanares et al. [30] performed a systematic review
of randomized clinical studies comparing lipid emulsions
with low versus high linoleic acid (n-6 polyunsaturated
fatty acid) levels in critically ill patients. However,
patients with elective surgery were excluded from the
analyses. Thus, the results of this systematic review may
not be applicable to elective surgery patients (studied in
the present trial). Overall, the lower linoleic acid
formulations in the studies demonstrated trends toward
lower mortality (relative risk [RR] 0.83, 95 % CI 0.62,
1.11, P = 0.2), duration of mechanical ventilation
(−2.57 days, 95 % CI −5.51, 0.37, P = 0.09), and ICU
length of stay (−2.31 days, 95 % CI −5.28, 0.66, P = 0.13).
There was no difference between formulations for total
infections (RR 1.13, 95%CI 0.87, 1.46, P = 0.35). Four of
the 12 studies in the review used an olive oil based lipid
emulsion and compared it to MCT/LCT (2 trials) or
soybean emulsion (2 trials). In this subset of studies,
there was no difference between groups for mortality or
ICU length of stay. Total infections tended to be higher
in the olive group (RR 1.23, 95 % CI 0.92, 1.63, P = 0.16)
whereas ventilation time was significantly lower in the
olive group (−6.47, 95 % CI −11.4, −1.5, P = 0.01).
The preparation time of PN solutions was significantly
less for OLIVE than for the SOYBEAN PN admixture.
One of the goals of this study was to assess current
methods of PN delivery in Chinese ICUs. Historically,
lipid emulsions have been administered separately from
the PN solution because of the storage requirements for
the emulsion. With the advent of multi-chamber PN sys-
tems it is now possible to provide a simultaneous and
continuous infusion of all nutrients using a single pump
and IV line [31]. Evidence suggests that the use of these
systems reduces the risk of microbial contamination due
to reduced handling, reduces the risk of bloodstream in-
fections, decreases the risk of error, decreases nursing
time, and decreases risk of physical instability of the PN
mixture [31–33]. Health economic investigations also
suggest that multi-chamber PN systems can reduce costs
associated with the manpower required to prepare com-
pounded PN admixtures [34, 35]. When compounding
PN admixtures, special attention needs to be paid to
aseptic technique, the order of mixing, the presence of re-
sidual air in the bag, the type of bag material, and the stor-
age conditions in order to prevent failure or
contamination of the admixture. These factors all affect
the amount of preparation time needed to prepare these
solutions [36, 37]. Further, preparation of compounded
admixtures requires specially trained staff and/or special-
ized automated equipment, whereas use of pre-prepared
multi-chamber bag systems only requires proper inspec-
tion of the solutions before initiation of the infusion [38].
No differences in the clinical outcomes of length of
hospitalization, mortality, or time to achieve tolerability
of oral nutrition were observed between the treatment
groups. However, other clinically relevant outcomes such
as quality of life, functional status, or rehospitalization
rates were not assessed in this study. Several small stud-
ies have reported that olive oil-based parenteral nutrition
is associated with reductions in the duration of mechan-
ical ventilation [22, 39] and length of stay in the ICU
[22]. In contrast, other larger studies have reported no
difference in the length of hospital stay or ICU length of
stay between olive oil-based and soybean oil-based ad-
mixtures [21, 26]. However, it is likely that the differ-
ences observed between the current study and prior
studies relate to the small sample sizes or to the specific
patient populations enrolled in the studies.
OLIVE was well tolerated and no significant differ-
ences in the frequency or severity of TEAEs were ob-
served between the treatment groups. In addition, the
frequency of TEAEs leading to discontinuation of study
drug was low. The incidence of hepatobiliary AEs was
low and not different between groups. The liver en-
zymes, alanine aminotransferase and aspartate amino-
transferase, were different between groups at baseline
but were not significantly different at Day 5 or EOT/
Day14. However, when analyzed by change from base-
line, values decreased more in the SOYBEAN group,
reflecting the higher baseline levels. The cause for the
higher baseline levels most likely reflects differences in
the underlying disease of the patients. The normalization
of these liver enzymes following surgery suggests that
they were related to the underlying disease. Alkaline
phosphatase and gamma-glutamyltransferase values were
similar at baseline. Levels were significantly higher in the
OLIVE group at Day 5 but not at EOT/Day 14. Day 5
values reflected only a portion of the patients. Mean
values for alkaline phosphatase were within normal
limits or minimally elevated. Values for gamma-
glutamyltransferase were elevated in both groups at
EOT/Day 14. The increase in both enzymes suggests
that both PN regimens were associated with mild chole-
stasis. Cholestasis has been associated with long-term
use of PN; however, it is unclear whether the changes re-
flect the use of PN or reflect changes following
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abdominal surgery. Importantly, total bilirubin was similar
between groups and most patients had values within nor-
mal limits. The clinical relevance of these findings is un-
clear. Perhaps a longer duration of PN would have revealed
additional information. Whether these early changes are
important in the context of long-term PN cannot be deter-
mined from this study; however, short-term PN with
OLIVE or SOYBEAN did not appear to negatively impact
liver function.
Clinical chemistry measures remained within normal
limits in both treatment groups for the duration of
the study. Small statistically significant differences
were noted between groups and once again, the clin-
ical relevance remains unclear. Of note, potassium
and phosphorus levels were better maintained within
normal ranges in the OLIVE group compared to the
SOYBEAN group. The better maintenance of phos-
phorus levels may have resulted from the use of or-
ganic phosphorus in OLIVE compared with inorganic
phosphorus in SOYBEAN. Organic phosphorus has a
longer circulation time than inorganic phosphorus
since it is not directly filtered in the urine, allowing
more time for entry of phosphorus into cells. Overall,
the results of the study suggest that OLIVE has a
safety profile that makes it suitable for use in ill
patients requiring PN.
The internal and external validity of this study are
strengthened by the prospective, randomized, controlled,
and multi-center study design. Although the study was
open label, which may have contributed to bias in the
reporting of treatment effects, it was not feasible to con-
duct a blinded study because it is standard practice that
the physician and/or nurse carefully inspect the PN for-
mulations to ensure that the integrity of the admixture
(technically an emulsion) is maintained throughout the
length of the infusion. In addition, the study is one of
the largest (N = 458) to compare the efficacy and safety
of two PN regimens in well-matched study populations
and there was consistency in the findings across a variety
of endpoints. The maximum duration of PN administra-
tion was 14 days, which is typical for elective surgery pa-
tients who usually receive PN for 7 to 10 days following
surgery, as enteral feeding is gradually increased. How-
ever, the relatively short duration of follow-up (a max-
imum of 14 days) may be considered a limitation.
Despite this, it is possible that a longer duration of PN
administration may have resulted in additional differ-
ences between the treatment groups.
In conclusion, OLIVE improved the anabolic/catabolic
status of hospitalized adults compared to SOYBEAN and
was well tolerated. OLIVE was non-inferior to SOYBEAN
for prealbumin and significantly increased prealbumin,
albumin, and IGF-I serum levels to a greater extent than
SOYBEAN. Inflammation and oxidation were similar in
each group, but infections were significantly lower with
OLIVE. The results of this study suggest that an olive oil-
based PN regimen improves nutritional outcomes, lowers
infections, is well tolerated, and confers greater ease-of-
use compared with a compounded soybean oil-based PN
regimen.
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